From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Botulinum Toxin Injections for Chronic Low Back Pain

Intramuscular injections of botulinum toxin A have been used successfully for a variety of conditions characterized by muscle spasm or dystonia. In this trial, researchers in Washington, DC, sought to determine whether botulinum toxin A also might be effective for patients with chronic low back pain, which can be associated with paraspinal muscle spasm.

Thirty-one patients, all of whom had had low back pain for at least 6 months (mean duration, 7 years) and unilateral predominance of pain, were enrolled. They were randomized to receive either botulinum toxin or saline placebo injected at 5 lumbar paravertebral sites. At 8 weeks, the proportion of patients with at least 50 percent improvement in pain (as measured on a visual analogue scale) was significantly greater in the botulinum group than in the placebo group (60 percent vs. 12.5 percent, P=0.009). Botulinum recipients also showed significantly greater improvement on a function scale for tasks of daily living. No side effects from botulinum toxin were noted. However, at 6-month follow-up, 6 of 10 botulinum responders noted that the benefit from the injections had subsided.

Comment: The authors believe that this is the first double-blind trial showing botulinum toxin A to be effective in chronic low back pain. The difference between groups was highly significant despite the small sample size, but the benefit was relatively short-lived. This study should be repeated in other settings; in addition, it would be useful to determine whether repeat injections are worthwhile.

— AS Brett

Published in Journal Watch General Medicine June 1, 2001

Citation(s):

Foster L et al. Botulinum toxin A and chronic low back pain: A randomized, double-blind study. Neurology 2001 May 56 1290-1293.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2001. Massachusetts Medical Society. All rights reserved.